• 1
    Brenner BM. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int. 1983; 23: 64755.
  • 2
    Olson JL, Hostetter TH, Rennke HG, Brenner BM, Venkatachalam MA. Altered glomerular permselectivity and progressive sclerosis following extreme ablation of renal mass. Kidney Int. 1982; 22: 11226.
  • 3
    Bochicchio T, Sandoval G, Ron O, Perez-Grovas H, Bordes J, Herrera-Acosta J. Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives. Kidney Int. 1990; 38: 8739.
  • 4
    Brenner BM, Cohen RA, Milford EL. In renal transplantation, one size may not fit all. J. Am. Soc. Nephrol. 1992; 3: 1629.
  • 5
    Modlin C, Goldfarb D, Novick AC. Hyperfiltration nephropathy as a cause of late graft loss in renal transplantation. World. J. Urol. 1996; 14: 25664.
  • 6
    Chiarelli F, Cipollone F, Romano F et al. Increased circulating nitric oxide in young patients with type 1 diabetes and persistent microalbuminuria: relation to glomerular hyperfiltration. Diabetes 2000; 49: 125863.
  • 7
    Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991; 303: 817.
  • 8
    Karlen J, Linne T, Wikstad I, Aperia A. Incidence of microalbuminuria in children with pyelonephritic scarring. Pediatr. Nephrol. 1996; 10: 705708.
  • 9
    Agewall S, Wikstrand J, Ljungman S, Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group. Am. J. Cardiol. 1997; 80: 1649.
  • 10
    Bello E, Caramelo C, Lopez MD et al. Induction of microalbuminuria by L-arginine infusion in healthy individuals: an insight into the mechanisms of proteinuria. Am. J. Kidney Dis. 1999; 33: 101825.
  • 11
    Hamar P, Peti-Peterdi J, Razga Z, Kovacs G, Heemann U, Rosivall L. Coinhibition of immune and renin-angiotensin systems reduces the pace of glomerulosclerosis in the rat remnant kidney. J. Am. Soc. Nephrol. 1999; 11(Suppl.): S2348.
  • 12
    Van Dijk MA, Peters DJ, Breuning MH, Chang PC. The angiotensin-converting enzyme genotype and microalbuminuria in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1999; 10: 191620.
  • 13
    Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J. Clin. Inves. 1990; 85: 5419.
  • 14
    Brouhard BH, Irwin KC, Cunningham RJ, Stowe NT. Use of angiotensin-converting enzyme inhibitors in chronic progressive renal disease. Cleve. Clin. J. Med. 1991; 58: 18490.
  • 15
    Hutchinson FN, Webster SK. Effect of ANG II receptor antagonist on albuminuria and renal function in passive Heymann nephritis. Am. J. Physiol. 1992; 263: F3118.
  • 16
    Irwin KC, Brouhard BH, Satoh S, Stowe NT. Effects of enalapril on adriamycin-induced nephrosis. Pediatr. Nephrol. 1992; 6: 44850.
  • 17
    Imanishi M, Yoshioka K, Okumura M et al. Mechanism of decreased albuminuria caused by angiotensin converting enzyme inhibitor in early diabetic nephropathy. Kidney Int. 1997; 63(Suppl.): S198200.
  • 18
    Amuchastegui SC, Azzollini N, Mister M, Pezzotta A, Perico N, Remuzzi G. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J. Am. Soc. Nephrol. 1998; 9: 194855.
  • 19
    Calvino J, Lens XM, Romero R, Sanchez-Guisande D. Long-term anti-proteinuric effect of losartan in renal transplant recipients treated for hypertension. Nephrol. Dial. Transplant. 2000; 15: 826.
  • 20
    Ersoy A, Dilek K, Usta M et al. Angiotensin-II receptor antagonist losartan reduces microalbuminuria in hypertensive renal transplant recipients. Clin. Transplant. 2002; 16: 202205.
  • 21
    Lum G. How effective are screening tests for microalbuminuria in random urine specimens? Ann. Clin. Lab. Sci. 2000; 30: 406411.
  • 22
    Kato T, Sato K, Kakinuma H, Kobayashi M, Tamura K. Radionuclide evaluation of the uretero-ileoceco- proctostomy (ileocecal rectal bladder). Int. J. Urol. 1994; 1: 15661.
  • 23
    Gates GF. Glomerular filtration rate. estimation from fractional renal accumulation of 99mTc-DTPA (Stannous). Am. J. Radiol. 1982; 138: 56570.
  • 24
    Taniwaki H, Ishimura E, Emoto M et al. Relationship between urinary albumin excretion and glomerular filtration rate in normotensive, nonproteinuric patients with type 2 diabetes mellitus. Nephron. 2000; 86: 3643.
  • 25
    Eberhard OK, Kliem V, Offner G et al. Assessment of long-term risks for living related kidney donors by 24-h blood pressure monitoring and testing for microalbuminuria. Clin. Transplant. 1997; 11: 4159.
  • 26
    Neugarten J, Srinivas T, Tellis V, Silbiger S, Greenstein S. The effect of donor gender on renal allograft survival. J. Am. Soc. Nephrol. 1996; 7: 31824.
  • 27
    Stigant CE, Cohen J, Vivera M, Zaltzman JS. ACE inhibitors and angiotensin II antagonists in renal transplantation. an analysis of safety and efficacy. Am. J. Kidney. Dis. 2000; 35: 5863.
  • 28
    Kasiske BL, Vazquez MA, Harmon WE et al. Recommendations for the outpatient surveillance of renal transplant recipients. J. Am. Soc. Nephrol. 2000; 11(Suppl.): S186.
  • 29
    Warram JH, Scott LJ, Hanna LS et al. Progression of microalbuminuria to proteinuria in type 1 diabetes. Diabetes. 2000; 49: 94100.
  • 30
    Hohage H, Kleyer U, Bruckner D, August C, Zidek W, Spieker C. Influence of proteinuria on long-term transplant survival in kidney transplant recipients. Nephron. 1997; 75: 16065.
  • 31
    Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int. 1997; 51: 215.
  • 32
    Satoh S, Kaneko T, Seino K et al. Angiotensin-converting enzyme inhibitor-induced anemia and treatment for erythrocytosis in renal transplant recipients. Jpn. J. Nephrol. 1995; 37: 3437.
  • 33
    Klaassen RJ, Van Gelder T, Rischen-Vos J, Deinum J. Man in’t Veld AJ, Weimar W. Losartan, an angiotensin-II receptor antagonist, reduces hematocrits in kidney transplant recipients with posttransplant erythrocytosis. Transplantation 1997; 64: 7802.